GLP-1 medications quiet the body's hunger. Exomind is a drug-free way to support the brain's role in impulse control and emotional eating — the constant mental chatter about food that often persists even after physical appetite has changed.
Whether you're on a GLP-1 program, coming off one, or have never taken one at all, food noise is the same experience: a constant background hum of thinking about food, cravings that show up whether or not you're hungry, and a pull toward eating that has more to do with your brain than your stomach. No injection reaches that part of the equation — but the same brain circuitry involved in impulse control and reward can be a target for Exomind.
Exomind uses ExoTMS™, a form of transcranial magnetic stimulation (TMS), to stimulate the dorsolateral prefrontal cortex (DLPFC) — a brain region involved in impulse control and dopamine regulation. The goal is to strengthen self-discipline and reduce the emotional and psychological pull toward food, making it easier to stick with the eating pattern you're working toward.
Honest framing: Exomind is FDA-cleared for the treatment of major depressive disorder. Its use for food noise and emotional eating is considered a supportive wellness application — it is not FDA-cleared for that indication and is not intended to diagnose, treat, cure, or prevent any disease, including obesity or eating disorders.
Every Exomind patient begins with a consultation covering your history, current weight-management approach (including any GLP-1 medication), and what food noise actually looks like for you day to day. Every patient is overseen by Medical Director Dr. Eric Evans, MD, a board-certified anesthesiologist with 30+ years of clinical experience.
Exomind works best as a series of sessions over several weeks, whether used alongside an active GLP-1 program or during the transition off one. Many patients notice a reduction in cravings within the first month; your provider will walk you through the recommended schedule during your consultation.
Exomind supports impulse control — it isn't a substitute for treatment of a diagnosed eating disorder. We'll help you find the right care if that's what you need.
In our clinical follow-up data, 100% of patients reported reduced food cravings at their one-month follow-up, with an average weight loss of 5 lbs and 78% of patients having lost weight. These are patient-reported outcomes from our own clinical data, not a guarantee — results depend on your overall approach to eating and weight management, and Exomind works as a complement to that approach, not a replacement for it.
Patient-reported outcomes from Exomind clinical follow-up data (BTL/EXOMIND). Individual results vary and are not guaranteed.
The most common side effects are mild scalp discomfort or headache during or shortly after a session. Seizure is a rare but serious risk associated with TMS, which is why every patient is screened for contraindications beforehand.
No. Exomind for food noise is available whether you're currently on a GLP-1 program, transitioning off one, or have never taken one — anyone dealing with persistent food noise or emotional eating can discuss candidacy during a consultation.
No. Exomind is intended as a complement to your weight-management approach, not a replacement for any medication. Any changes to your GLP-1 prescription should be made with your prescribing provider.
It begins with a free consultation — a conversation, not a commitment. If Exomind is appropriate, treatment can often begin within days.
Your free consultation is a no-pressure conversation about your relationship with food and whether Exomind is a reasonable next step.
Request Your Free ConsultationCall (435) 522-5190This page is for educational purposes and is not medical advice. Exomind is FDA-cleared for the treatment of major depressive disorder. Its use for food noise, emotional eating, and weight management support is a supportive wellness application, is not FDA-cleared for that indication, and is not intended to diagnose, treat, cure, or prevent any disease, including obesity or eating disorders. Outcome statistics cited are from BTL/EXOMIND clinical follow-up data and reflect averages; individual results are not guaranteed. Reading this page or submitting a form does not create a provider-patient relationship.